LifeMine’s chairman and co-founder Rick Klausner has co-led a round that included multiple corporates and pushed the overall equity to $120m.

LifeMine Therapeutics, a US-based small molecule drug developer based on research at Harvard University, has secured $50m of series B funding co-led by Rick Klausner, a co-founder and the chairman. Milky Way Investments co-led the round, while nternet and technology group Alphabet and pharmaceutical firms WuXi AppTec and Merck & Co took part through respective…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.